Table 1.
Characteristics of Patients Who Experienced Serious Immune-Related Adverse Events Requiring Treatment Delay
| Retreatment | Discontinuation | P value | |
|---|---|---|---|
| No. of patients; No. (%) | 38 | 30 | |
| Median age, years (range) | 64 (49–83) | 66 (42–84) | 0.59 |
| Sex, female; No. (%) | 18 (47) | 11 (37) | 0.46 |
| Smoking history, No. (%) | 0.51 | ||
| Yes | 33 (87) | 24 (80) | |
| No | 5 (13) | 6 (20) | |
| Histology, No. (%) | 0.06 | ||
| Adenocarcinoma | 23 (61) | 26 (87) | |
| Squamous | 11 (29) | 4 (13) | |
| LCNEC or NOS | 4 (10) | 0 (0) | |
| Immunotherapy treatment data, No. (%) | 0.18 | ||
| Anti–PD-1 or Anti–PD-L1 | 24 (63) | 24 (80) | |
| Combination w/ anti–CTLA4 | 14 (37) | 6 (20) | |
| Line of therapy, No. (%) | 0.007 | ||
| First | 25 (66) | 9 (30) | |
| Second and beyond | 13 (34) | 21 (70) | |
| Best overall response, No. (%) | 0.62 | ||
| CR or PR | 18 (47) | 12 (40) | |
| SD or PD | 20 (53) | 18 (60) |
Abbreviations: LCNEC, large-cell neuroendocrine cancer; NOS, not otherwise specified carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.